Introduction

Every pregnant woman has a risk of having a fetus with chromosomal abnormalities. Chromosomal anomalies are detected in approximately 50-60% of spontaneous abortions and 2-4% of all newborns. Fetuses with chromosomal abnormalities are at risk for adverse fetal outcomes, and these abnormalities cause 20% of deaths in the first year of life [1-4]. Chromosomal abnormalities represent approximately 15% of the major congenital anomalies diagnosed before the age of 1 year in Europe [5]. The traditional cytogenetic analysis enables to identify numerical and structural disorders of chromosomes [6,7]. At the same time, molecular DNA techniques enable the detection of single-gene diseases [8]. Approximately 90% of chromosomal anomalies are numerical disorders of 13th, 18th, 21st chromosomes, and sex chromosomes (X, Y). Trisomies 13, 18, 21 are the most common autosomal trisomies.
Material and methods

This study included a retrospective analysis of 1666 pregnant women who underwent prenatal invasive diagnostic procedures in the perinatology department of Kanuni Sultan Süleyman Training and Research Hospital between March 2016 and November 2018. Data were evaluated in terms of indications and results of these procedures. Ethical approval for this study was obtained from the ethics committee of our hospital (2019/03/43). Before the procedure, a detailed US examination was performed to detect structural abnormalities in each patient with invasive procedure indications. Indications for the prenatal invasive procedure were as follows: cystic hygroma, advanced maternal age, presence of fetal anomalies in ultrasonography, increased risk for aneuploidy in maternal serum screening tests, history of a child with chromosomal or structural abnormalities, increased nuchal translucency (NT), fetal anemia, suspicion of fetal infection, and maternal anxiety.

Advanced maternal age was defined as 35 years and above, and maternal serum screening tests were not performed on these patients. The presence of a fetal anomaly in the US was defined as a major anomaly or the presence of ≥2 minor markers in US examination. US minor markers, known as soft markers, included single umbilical artery (SUA), mild pyelectasis (renal pelvis ≥4 mm), unilateral or bilateral choroid plexus cysts (CPC) (≥2 mm), echogenic bowel, and echogenic intracardiac focus [13]. We included patients with abnormal US findings in a single group, even if they had other indications. Maternal serum prenatal screening (double, triple, and quadrupe test) results were collected in a single group. The first trimester combined risk or second-trimester biochemical risk was defined as 1/270 for down syndrome and 1/100 for trisomy 13 and 18. Nuchal translucency increase was accepted as ≥3.5 mm. All pregnant women with invasive procedure indication and their spouses were informed in detail about the risk of a possible chromosomal abnormality, the method of performing the invasive procedure, the possible benefits and risks, and they were provided with genetic counseling. Informed consent forms were signed by couples who accepted the invasive procedure. Before the procedure, all pregnant women were evaluated in terms of blood group and Rh incompatibility, and 300 mcg anti D Ig was administered to pregnant women with Rh incompatibility. Procedures were performed using the Voluson 730 Expert (General Electric Healthcare, Milwaukee, WI, USA) device and 3.5 MHz transabdominal convex probes with the US.

Before the procedure was performed, US has performed on all patients again, and according to the procedure to be applied, the most appropriate place for the procedure was determined by evaluating the amniotic fluid, the location of the placenta, and the position of the fetus. CVS was performed between 11-14 weeks of gestation, under sterile conditions, using an 18 Gauge (G) spinal needle only transabdominal. AS was preferred in patients not suitable for CVS sampling with active vaginal bleeding and patients with posterior placenta and umbilical cord, and transplacentally in unsuitable cases. A total of 27.5 amniotic fluid were aspirated into 2.5 ml (x1) and 5 ml (x5) sterile syringes. CS was performed transabdominal, under sterile conditions, in pregnancies above the 22nd gestational week, by entering the umbilical vein from the umbilical cord’s placenta insertion area or the free-floating part of the cord with a 22 Gauge (G) spinal needle. 2.5 ml of fetal blood was collected into the syringe washed with sterile heparin. A maximum of two-needle entries was made to obtain the material.

The procedure was repeated 1 week later in cases that could not be successful. The material samples taken were delivered to the genetic laboratory. Patients were discharged on the same day after being observed in the hospital for 2 hours after the procedure. Maternal characteristics such as age, gravity, and parity of the patients indicate a prenatal invasive procedure, type of procedure, and results were recorded.

Statistical analysis

Nominal and ordinal parameters were described with frequency analysis, whereas maternal age was described with mean and standard deviation. The Chi-square likelihood ratio was used for comparison of nominal and ordinal differences. Statistical analysis of the data was performed using SPSS 21.0 (SPSS Inc., Chicago, IL, USA) package program at a 95% confidence interval. Differences were considered statistically significant at p-value <0.05.

Results

During the study period, 1666 patients underwent prenatal invasive procedures. Maternal age, indications, and results of prenatal invasive diagnostic procedures are given in Table 1.

AS was performed to 1060 (63.6%) patients, CVS to 299 (17.9%), and CS to 307 (18.4%) patients. The mean age of the study cohort was 31.59±6.73 years. Among the prenatal invasive procedure indications, the most frequent indication was US abnormalities, with a rate of 48.3% (n = 805). The other common prenatal invasive procedure indications were advanced maternal age (23.9%, n = 399), and maternal serum screening test with high risk for aneuploidy (21.1%, n = 351). A normal karyotype was detected in 85% (n = 1416) of 1666 pregnant women who underwent invasive procedures and chromosomal abnormalities were found in 12.2% (n = 204). Abnormal karyotype results were found in...
111 (10.5%) of 1060 patients who underwent AS, 87 (29.1%) of 299 patients who underwent CVS, and 52 (16.9%) of 307 patients who underwent CS.

Table 1. Maternal age, indications and results of prenatal invasive diagnostic procedures

| Parameter                                      | Value                |
|-----------------------------------------------|----------------------|
| Maternal age, years                          | 31.59±6.73           |
| Prenatal invasive diagnostic method, n (%)    |                      |
| Amniocentesis                                 | 1060 (63.6)          |
| Cordocentesis                                 | 307 (18.4)           |
| Chorionic villus sampling                     | 299 (17.9)           |

**Indication, n (%)**

| Abnormal US findings                         | 805 (48.3)           |
| Advanced maternal age                        | 399 (23.9)           |
| Screening test positivity                    | 351 (21.1)           |
| Previous history of fetus with chromosomal or structural anomaly history | 36 (2.2) |
| Suspected congenital infection               | 20 (1.2)             |
| Fetal anemia                                 | 20 (1.2)             |
| Maternal anxiety                             | 17 (1.0)             |
| Increased NT                                 | 10 (0.6)             |
| Cystic hygroma                               | 8 (0.5)              |

**Results, n (%)**

| Normal                                       | 1416 (85.0)          |
| Down syndrome                                | 94 (5.6)             |
| Edwards syndrome                             | 35 (2.1)             |
| Non-growth samples in culture                | 31 (1.9)             |
| Inversion                                    | 18 (1.1)             |
| Turner syndrome                              | 17 (1.0)             |
| Maternal contamination                       | 15 (0.9)             |
| Translocation                                | 10 (0.6)             |
| Triploidy                                    | 10 (0.6)             |
| Patau syndrome                               | 9 (0.54)             |
| Insertion                                    | 4 (0.24)             |
| Trisomy                                      | 3 (0.18)             |
| Deletion                                     | 2 (0.12)             |
| Pallister Killian syndrome                   | 1 (0.06)             |
| Klinefelter syndrome                         | 1 (0.06)             |

Of 50 patients with insufficient material, culture failure, procedural failure, and maternal contamination, four patients agreed to undergo a second invasive procedure, and the results were detected as a normal karyotype. Fetal karyotype determination failed in 46 (2.76%) patients due to exhibiton no growth in the sample culture; 10 (0.6%) patients in AS group, 17 (1%) patients in CVS group, and 19 (1.1%) patients in CS group. Of those, 31 patients (1.9%) due to culture failure, insufficient material, procedure failure, and 15 (0.9%) due to maternal contamination. While 82.9% (169/204) of 204 fetuses with chromosomal anomalies have numerical chromosome anomalies, 17.1% (35/204) of fetuses with chromosomal anomalies had structural chromosome anomalies. The most common numerical chromosomal abnormality trisomy 21 (46%, 94/204), and the most common structural chromosomal abnormality was inversions (8.8%, 18/204).

When we analyzed the indication differences between the prenatal invasive diagnostic procedure groups, in AS group, advanced maternal age (30.9%, n= 328), maternal serum screening test with high risk for aneuploidy (25.8%, n= 273), and maternal anxiety (1.4%, n= 15) was significantly higher than CS and CVS groups (p<0.05) (Table 2). In the CVS group, the previous history of children with chromosomal or structural anomalies (5.4%, n= 16), increased NT (2%, n= 6), and cystic hygroma (1%, n= 3) was significantly higher than AS and CVS groups (p<0.05). In the CS group, abnormal US findings (77.2%, n= 237) and fetal anemia (5.5%, n= 17) was significantly higher than the other groups (p<0.05).

Table 2. The indications and results of prenatal invasive diagnostic procedures of the participants

| Parameter                                      | Value                |
|-----------------------------------------------|----------------------|
| Maternal age, years                          | 31.59±6.73           |
| Prenatal invasive diagnostic method, n (%)    |                      |
| Amniocentesis                                 | 1060 (63.6)          |
| Cordocentesis                                 | 307 (18.4)           |
| Chorionic villus sampling                     | 299 (17.9)           |

**Indication, n (%)**

| Abnormal US findings                         | 805 (48.3)           |
| Advanced maternal age                        | 399 (23.9)           |
| Screening test positivity                    | 351 (21.1)           |
| Previous history of fetus with chromosomal or structural anomaly history | 36 (2.2) |
| Suspected congenital infection               | 20 (1.2)             |
| Fetal anemia                                 | 20 (1.2)             |
| Maternal anxiety                             | 17 (1.0)             |
| Increased NT                                 | 10 (0.6)             |
| Cystic hygroma                               | 8 (0.5)              |

**Results, n (%)**

| Normal                                       | 1416 (85.0)          |
| Down syndrome                                | 94 (5.6)             |
| Edwards syndrome                             | 35 (2.1)             |
| Non-growth samples in culture                | 31 (1.9)             |
| Inversion                                    | 18 (1.1)             |
| Turner syndrome                              | 17 (1.0)             |
| Maternal contamination                       | 15 (0.9)             |
| Translocation                                | 10 (0.6)             |
| Triploidy                                    | 10 (0.6)             |
| Patau syndrome                               | 9 (0.54)             |
| Insertion                                    | 4 (0.24)             |
| Trisomy                                      | 3 (0.18)             |
| Deletion                                     | 2 (0.12)             |
| Pallister Killian syndrome                   | 1 (0.06)             |
| Klinefelter syndrome                         | 1 (0.06)             |

We also summarized the prenatal invasive diagnostic procedure results of the participants in Table 2. Normal karyotype results were significantly higher in the AS group than CS and CVS groups (p<0.05). In the CVS group, trisomy 21, trisomy 18, abnormal US findings (14.8%, 37 patients), and advanced maternal age (17.2%, 43 patients).

**Discussion**

The most common indications for the prenatal invasive diagnostic procedure in our study are abnormal US findings (48.3%), advanced maternal age (23.9%), and maternal serum screening test with high risk for aneuploidy (21.1%). Previous studies reported that the most common indications for these interventions were advanced maternal age and maternal serum screening tests with high risk for aneuploidy [6,14-16]. As a prenatal invasive diagnostic procedure indication, the rate of maternal serum screening tests with high risk for aneuploidy has been reported to vary between 3.48% and 28.2% in other studies [6,17-21].
reason for this difference may be that previous studies more often focused on AS procedure results. Abnormal US findings are mostly detected late in the second trimester or third trimester of pregnancy. Therefore, CS, which is an invasive procedure appropriate in gestational weeks, was not included in the studies. Another reason why the most frequent indication was found to be different in our study is the widespread use of extracellular fetal DNA tests in recent years. This widespread use may cause decreased invasive intervention rates may due to advanced maternal age or maternal serum screening tests with high risk for aneuploidy [22]. We consider that our high rate of abnormal US findings was because our clinic is a tertiary referral clinic and the pregnant women with abnormal US findings were commonly referred to us.

Table 3. The distribution of the prenatal invasive diagnostic procedure results according to the indications*

| Results                  | Total |
|--------------------------|-------|
| Normal                   | Abnormal |  |
| Abnormal US finding      | 645 (45.6%) | 160 (64.0%) | 805 (48.3%) |
| Advanced maternal age    | 356 (25.1%) | 43 (17.2%) | 399 (23.9%) |
| Screening test positivity| 314 (22.2%) | 37 (14.8%) | 351 (21.1%) |
| Previous history of      | 31 (2.2%) | 5 (2.0%) | 36 (2.2%) |
| pregnancy with            |          |          |          |
| chromosomal or            |          |          |          |
| structural anomaly        |          |          |          |
| Suspected congenital      | 20 (1.4%) | 0 (0%) | 20 (1.2%) |
| infection                 |          |          |          |
| Fetal anemia              | 19 (1.3%) | 1 (0.4%) | 20 (1.2%) |
| Maternal anxiety          | 16 (1.1%) | 1 (0.4%) | 17 (1.0%) |
| Increased NT              | 9 (0.6%) | 1 (0.4%) | 10 (0.6%) |
| Cystic hygroma            | 6 (0.4%) | 2 (0.8%) | 8 (0.5%) |

*p value is <0.001

In our study, we detected 12.2% of fetuses with chromosomal anomalies in prenatal diagnostic invasive procedures. The chromosomal anomaly was detected in 10.5% of patients who underwent AS, 29.1% of patients who underwent CVS, and 16.9% of patients who underwent CS. In the literature, the rate of chromosomal anomaly detection in invasive procedures ranges from 0.9% to 20.27% [17,23,24]. The rate of detecting chromosomal anomalies in our study was found to be higher than reported in the literature. We consider that the higher rate is due to our proper invasive procedure indications, the widespread use of prenatal serum screening tests in our clinic, and our experienced team in detecting abnormal US findings. Among the indications, the rate of abnormal karyotype results was higher in patients with a history of cystic hygroma, abnormal US findings, and a fetus with structural or chromosomal abnormalities.

The chromosomal anomaly was found in 19.9% of pregnant women with abnormal US findings. This rate has been reported in the literature varying between 4.43% and 22.7% [6,10]. The reason for these different rates may be that some studies did not include CS procedures for anomalies detected in advanced gestational weeks and did not perform karyotype determination due to minor US markers. Previous studies reported that the use of AS was more frequent than CVS and CS [16]. Researches stated that AS is an easily applicable method, and the morbidity risk is lower than the other procedures. Likewise, AS was the most common diagnostic procedure in our study.

Conclusion

The results of the current study show that AS is the most common prenatal diagnostic invasive procedure. We obtained the highest fetal chromosomal anomaly rate in patients who experienced CVS. Abnormal US findings were the most common prenatal invasive diagnostic procedure indication in our study. Choosing the most appropriate invasive procedure for a patient with a high risk for chromosomal anomaly is related to the obstetricians’ experience, medical history of the patient, the gestational week at admission, maternal prenatal serum screening test results, and abnormal US findings.

Disclosure

Authors have no potential conflicts of interest to disclose.

References

[1] Hernández-Herrera RJ, Rojas-Patián L, Garza-Pérez RM, Dávila-Rodríguez M, Cortés-Gutiérrez EI, García-Rodríguez EO, et al. Anormalidades cromosómicas en pacientes de un hospital de ginecoobstetricia [Chromosomal abnormalities in patients from Obstetrics and Gynaecology hospital]. Rev Med Inst Mex Seguro Soc. 2014;52(1):90-3.
[2] Nikitina TV, Sazhenova EA, Tolmacheva EN, Sukhanova VN, Kashevarov AA, Skyryabin NA, et al. Comparative Cytogenetic Analysis of Spontaneous Abortions in Recurrent and Sporadic Pregnancy Losses. Biomed Hub. 2016;1(1):1-11.
[3] Behram M, Oğlak SC, Gedik Özköse Z, Süzen Çaypinar S, Başkırkan Y, Sezer S, Bademkiran C, Özdemir İsmail. The Distribution of Congenital Malformations in Adolescent Pregnancies: A Single Tertiary Center Experience in Turkey. Aegaean J Obstet Gynecol. 2020;2(3):14-8.
[4] Oğlak SC, Bademkiran MH, Obut M. Predictor variables in the success of slow-release dinoprostone used for cervical ripening in intrauterine growth restriction pregnancies. J Gynecol Obstet Hum Reprod. 2020;49(6):101739.
[5] Wellesley D, Dolk H, Boyd PA, Greenlees R, Haessler M, Nelen V, et al. Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe. Eur J Hum Genet. 2012;20(5):521-526.
[6] Zhang S, Yin M, Xu JZ, Lei CX, Wu JP, Sun XX, et al. Cytogenetic analysis for fetal chromosomal abnormalities by amniocentesis: Review of over 40,000 consecutive cases in a single center. Reprod Dev Med. 2017;1(2):84-88.
[7] Lopez M, Coll O. Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations. Fetal Diagn Ther. 2010;28:1-8.
[8] Norton ME, Rink BD. Changing indications for invasive testing in an era of improved screening. Semin Perinatol 2016;40:56-66.
[9] Summers AM, Langlois S, Wyatt P, Wilson RD. Prenatal screening for fetal aneuploidy. Society of Obstetricians and Gynaecologists of Canada. J Obstet Gynaecol Can 2007;29:146-79.
[10] Özcan HÇ, Uğur MG, Sucu S, Mustafa A, Bayramoğlu Tepe N, et al. Summary of 2185 prenatal invasive procedures in a single center: A retrospective analysis. Turk J Obstet Gynecol. 2017;14(2):114-120.
[11] Ghi T, Sotiriadis A, Calda P, Da Silva Costa F, Raine-Fenning N, Alfieric Z, McGillivray G; International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis. Ultrasound Obstet Gynecol. 2016;48(2):256-68.
[12] Wilson RD, Gagnon A, Audibert F, Campagnolo C, Carroll J; GENETICS COMMITTEE. Prenatal Diagnosis Procedures and Techniques to Obtain a Diagnostic Fetal Specimen or Tissue: Maternal and Fetal Risks and Benefits. J Obstet Gynaecol Can. 2015;37(7):656-668.
[13] Tosun M, Kurtoglu Ozdes E, Malatyalioglu E, Yavuz E, Celik H, Bildircin FD, et al. Long-Term Outcome of Fetuses with Soft Marker and Without Genetic or Structural
Abnormality. J Obstet Gynaecol India. 2019;69(1):56-61.
[14] Alfirevic Z, Navaratnam K, Mujiznovic F. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev. 2017;9(9):CD003252.
[15] Jummaat F, Ahmad S, Mohamed Ismail NA. 5-Year review on amniocentesis and its maternal fetal complications. Horm Mol Biol Clin Investig. 2019;40(2)://j/hmbci.2019.40.issue-2/hmbci-2019-0006/hmbci-2019-0006.xml.
[16] İnan C, Sayın NC, Gürkan H, Dolgun ZN, Erzincan SG, Uzun I, et al. Evaluation of Invasive Prenatal Test Indications and Results at a Tertiary Center in the Thrace Region of Turkey. J Clin Obstet Gynecol. 2019;29(1):8-16.
[17] Mademont-Soler I, Morales C, Clusellas N, Soler A, Sánchez A, Group of Cytogenetics from Hospital Clinic de Barcelona, et al. Prenatal cytogenetic diagnosis in Spain: Analysis and evaluation of the results obtained from amniotic fluid samples during the last decade. Eur J Obstet Gynecol Reprod Biol. 2011;157:156-60.
[18] An N, Li LL, Wang RX, Li LL, Yue JM, Liu RZ, et al. Clinical and cytogenetic results of a series of amniocentesis cases from Northeast China: A report of 2500 cases. Genet Mol Res 2015;14:15660-7.
[19] Daniilidis A, Karydas H, Zournatzi V, Tantanasis T, Giannoulis C, Tzafettas J. A four-year retrospective study of amniocentesis: one centre experience. Hippokratia. 2008;12(2):113-115.
[20] Boso B, Soysal C, Sucu M, Demir SC. Chromosome analysis results of first-second trimester anomaly screening tests: Single center experience. Ann Med Res. 2020;27(5):1507-13.
[21] Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center’s 16-year experience. Obstet Gynecol. 2008;111:589-95.
[22] American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012;120(6):1532-4.
[23] Ocak Z, Ozlü T, Yazıcıoğlu HF, Ozyurt O, Ayyuğ M. Clinical and cytogenetic results of a large series of amniocentesis cases from Turkey: Report of 6124 cases. J Obstet Gynaecol Res. 2014;40:139-46.
[24] Han SH, An JW, Jeong GY, Yoon HR, Lee A, Yang YH, et al. Clinical and cytogenetic findings on 31,615 mid-trimester amniocenteses. Korean J Lab Med. 2008;28:378-85.